Ademoğlu Evin, Ozbey Neşe, Erbil Yeşim, Tanrikulu Sevda, Barbaros Umut, Yanik Burcu Tulumoğlu, Bozbora Alp, Ozarmağan Selçuk
Istanbul University, Istanbul Medical Faculty, Department of Biochemistry, Turkey.
Eur J Intern Med. 2006 Dec;17(8):545-50. doi: 10.1016/j.ejim.2006.04.013.
The aim of our study was to evaluate the oxidant/antioxidant status of thyroid tissue in Graves' disease (GD) patients and to compare the results of GD thyroid tissue with plasma of patients and healthy controls.
We studied 25 consecutive patients with GD hyperthyroidism who underwent surgical treatment. The patients were divided into groups according to the duration of antithyroid drug treatment, the type of antithyroid drugs used, the presence of ophthalmopathy, and recurrence after a complete course of antithyroid drugs. Thiobarbituric acid-reacting substances (TBARS), glutathione peroxidase (GPx) activity, superoxide dismutase (SOD) activity, and total thiol (t-SH) content of tissue and plasma samples were determined.
TBARS concentrations were found to be significantly increased in GD patients' plasma compared with controls' plasma (0.1+/-0.02 nmol/mg protein vs. 0.062+/-0.01 nmol/mg protein). Significantly decreased t-SH concentrations were measured in GD patients' plasma compared with controls (8.26+/-1.9 nmol/mg protein vs. 13.03+/-3.3 nmol/mg protein). Tissue TBARS, t-SH, GPx, and SOD measurements in GD patients indicated significantly increased concentrations compared with the plasma levels of patients. Patients with shorter treatment duration before the operation had significantly increased plasma and tissue TBARS and decreased plasma and tissue t-SH concentrations. Patients on propylthiouracil treatment had significantly lower plasma and tissue concentrations of TBARS than patients on methimazole. Patients with recurrence had significantly higher plasma and tissue TBARS and lower plasma and tissue t-SH concentrations than patients treated for the first time.
In euthyroid GD patients on antithyroid drugs, increased oxidative stress and a compensatory increase in the antioxidant defense system are more prominent in thyroid tissue than in plasma. Patients who relapsed had markers indicating increased oxidative stress. Thus, ongoing autoimmunity may contribute to increased oxidative stress in GD patients, even in the euthyroid state.
我们研究的目的是评估格雷夫斯病（GD）患者甲状腺组织的氧化/抗氧化状态，并将GD甲状腺组织的结果与患者血浆及健康对照者的血浆进行比较。
我们研究了连续25例接受手术治疗的GD甲亢患者。根据抗甲状腺药物治疗的持续时间、所用抗甲状腺药物的类型、眼病的存在情况以及抗甲状腺药物一个完整疗程后的复发情况将患者分组。测定组织和血浆样本中的硫代巴比妥酸反应物质（TBARS）、谷胱甘肽过氧化物酶（GPx）活性、超氧化物歧化酶（SOD）活性以及总巯基（t-SH）含量。
与对照组血浆相比，GD患者血浆中的TBARS浓度显著升高（0.1±0.02 nmol/mg蛋白对0.062±0.01 nmol/mg蛋白）。与对照组相比，GD患者血浆中测得的t-SH浓度显著降低（8.26±1.9 nmol/mg蛋白对13.03±3.3 nmol/mg蛋白）。GD患者的组织TBARS、t-SH、GPx和SOD测量结果表明，与患者血浆水平相比，其浓度显著升高。术前治疗持续时间较短的患者血浆和组织中的TBARS显著升高，血浆和组织中的t-SH浓度降低。接受丙硫氧嘧啶治疗的患者血浆和组织中的TBARS浓度显著低于接受甲巯咪唑治疗的患者。复发患者的血浆和组织TBARS显著高于首次治疗的患者，血浆和组织t-SH浓度则较低。
在接受抗甲状腺药物治疗的甲状腺功能正常的GD患者中，甲状腺组织中的氧化应激增加以及抗氧化防御系统的代偿性增加比血浆中更为突出。复发患者具有氧化应激增加的标志物。因此，即使在甲状腺功能正常的状态下，持续的自身免疫可能导致GD患者氧化应激增加。
